Elutia Inc. (ELUT)
| Market Cap | 44.16M |
| Revenue (ttm) | 12.46M |
| Net Income (ttm) | 49.84M |
| Shares Out | 44.21M |
| EPS (ttm) | 0.91 |
| PE Ratio | 0.89 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 91,816 |
| Open | 0.936 |
| Previous Close | 0.948 |
| Day's Range | 0.936 - 0.992 |
| 52-Week Range | 0.500 - 2.640 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 13, 2026 |
About ELUT
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac pat... [Read more]
Financial Performance
Financial StatementsNews
Elutia Transcript: Planet MicroCap Las Vegas 2026
A drug-eluting biologic platform is being advanced for breast reconstruction, addressing a $1.5 billion U.S. market with high infection rates. The product delivers local antibiotics via mesh, with regulatory approval expected next year and a focused commercialization plan targeting top centers.
Elutia to Present at Planet MicroCap Showcase 2026 on June 17th
GAITHERSBURG, Md., June 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chi...
Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., May 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awa...
Elutia Transcript: 16th Annual LD Micro Invitational Conference
A proven antibiotic-eluting matrix platform is being adapted for breast reconstruction, targeting a $1.5 billion U.S. market with high infection rates. FDA approvals are expected within a year, with a cost-neutral, high-margin commercialization strategy focused on top hospitals.
Elutia Earnings Call Transcript: Q1 2026
Q1 2026 saw 6% revenue growth, improved gross margins, and strong liquidity. Regulatory progress and manufacturing advances support confidence in NXT-41x, with FDA clearance and commercialization targeted for 2026–2027. Strategic divestitures are underway.
Elutia Earnings release: Q1 2026
Elutia released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Elutia Slides: Q1 2026
Elutia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.
Elutia Quarterly report: Q1 2026
Elutia has published its Q1 2026 quarterly earnings report on May 14, 2026.
Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market
NXT-41 review advancing collaboratively with FDA, informing NXT-41x submission preparations Brought a new automated manufacturing process online, supporting a gross margin target of more than 80% at s...
Elutia to Present at the 16th Annual LD Micro Invitational on May 18th
GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chie...
Elutia to Present at the 16th Annual LD Micro Invitational May 18th
Gaithersburg, Maryland--(Newsfile Corp. - May 14, 2026) - Elutia Inc. (NASDAQ: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills...
Elutia to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
GAITHERSBURG, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its...
Elutia Proxy statement: Proxy filing
Elutia filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Elutia Proxy statement: Proxy filing
Elutia filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
Elutia Transcript: Sidoti March Small-Cap Virtual Conference
A new drug-eluting biologic for breast reconstruction aims to address a $1.5B market with high infection rates by delivering antibiotics directly at the surgical site. FDA approval for the base matrix is expected this year, with the drug-eluting version targeted for next year.
Elutia to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19
GAITHERSBURG, Md., March 17, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Ch...
Elutia announces grants of inducement awards
Elutia (ELUT) announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc. 2026 Inducement Award Plan. The awards were…
Elutia Earnings Call Transcript: Q4 2025
Revenue grew 16% year-over-year to $3.3M with improved gross margins and reduced net loss. Strategic sale of BioEnvelope enabled debt repayment and a strong cash position, supporting the focus on NXT-41x for the large breast reconstruction market.
Elutia Annual report: Q4 2025
Elutia has published its Q4 2025 annual report on March 11, 2026.
Elutia Earnings release: Q4 2025
Elutia released its Q4 2025 earnings on March 11, 2026, summarizing the period's financial results.
Elutia Slides: Q4 2025
Elutia has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 11, 2026.
Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – – $44.4 million in cash and escrowed proceeds at year...
Elutia regains compliance with Nasdaq listing requirements
Elutia (ELUT) announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the…
Elutia Regains Compliance with Nasdaq Listing Requirements
GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received not...
Elutia appoints Ligotti as Chief Commercial Officer
Elutia (ELUT) announced the appointment of Pete Ligotti as Chief Commercial Officer. Ligotti will lead the commercialization for NXT-41x.